Browsing by Author Goldinger, Anita

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2017Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosisBasuki, Monica; Booth, David; Burke, Teresa E; Edwards, James; Fewings, Nicole; Gatt, Prudence; McKay, Fiona; Parnell, Grant; Schibeci, Stephen; Stewart, Graeme; Vucic, Steve; Baranzini, Sergio; Fabis-Pedrini, Marzena; Goldinger, Anita; Kermode, A; Manrique, C; McCauley, Jacob; Nickles, D; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead)Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis, Data in Brief, vol.11, N/A, 2017,pp 364-370
2016The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapiesBasuki, Monica; Booth, David; Burke, Therese; Fewings, Nicole; Gatt, Prudence; McKay, Fiona Catherine; Parnell, Grant; Schibeci, Stephen; Stewart, Graeme; Vucic, Steve; Fabis-Pedrini, Marzena; Goldinger, Anita; Kermode, Allan; Powell, Jospeh; Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead)The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies, Clinical Immunology, vol.163, N/A, 2016,pp 96-107